Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.

Aging - 3 Feb 2020

Zhu Gongmin, Pei Lijiao, Li Yuan, Gou Xin

Abstract excerpt

Bladder cancer is a leading cause of morbidity and mortality worldwide. Currently, immunotherapy has become a worthwhile therapy for bladder cancer. Tumor mutation burden (TMB) has been regarded as the most prevalent biomarker to predict immunotherapy. Bladder cancer is reported to have the third highest mutation rate. However, whether these gene mutations are related to TMB and immune response remain unknown. In...

Topics

Join the communities discussing this publication.

Biomarkers, Tumor
Carcinoma, Transitional Cell
Databases, Genetic
E1A-Associated p300 Protein
Immunity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Proportional Hazards Models

Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32012118
DOI: 10.18632/aging.102728
PMCID: PMC7041765

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.PMID 32012118Read ↗

Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation.Semantic proximity Read ↗

Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.Semantic proximity Read ↗

Identification of potential therapeutic targets in urothelial bladder carcinoma of Chinese population by targeted next-generation sequencing.Semantic proximity Read ↗

Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes.Semantic proximity Read ↗

Identification of RB1 Gene as a Immune-Related Prognostic Signature Based on Tumor Mutation Burdens in Bladder CancerSemantic proximity Read ↗

Significance of KDM6A Mutation in Bladder Cancer Immune EscapeSemantic proximity Read ↗

Analysis of the Relationship between Bladder Cancer Gene Mutation and Clinical Prognosis by High-Throughput Sequencing.Semantic proximity Read ↗

Significance of KDM6A Mutation in Bladder Cancer Immune EscapeSemantic proximity Read ↗

Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.Semantic proximity Read ↗

Identification of NTRK3 as a potential prognostic biomarker associated with tumor mutation burden and immune infiltration in bladder cancerSemantic proximity Read ↗

Identification and validation of RB1 as an immune-related prognostic signature based on tumor mutation burdens in bladder cancer.Semantic proximity Read ↗

Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.